E Fund Management Co. Ltd. Takes Position in Kymera Therapeutics, Inc. $KYMR

E Fund Management Co. Ltd. acquired a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) in the 2nd quarter, Holdings Channel.com reports. The firm acquired 5,209 shares of the company’s stock, valued at approximately $597,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. BlackRock Inc. bought a new stake in Kymera Therapeutics during the second quarter valued at about $635,067,000. Baker BROS. Advisors LP raised its stake in shares of Kymera Therapeutics by 30.2% in the fourth quarter. Baker BROS. Advisors LP now owns 8,657,242 shares of the company’s stock worth $673,620,000 after buying an additional 2,005,813 shares during the period. Avoro Capital Advisors LLC lifted its position in shares of Kymera Therapeutics by 17.7% during the 4th quarter. Avoro Capital Advisors LLC now owns 7,474,747 shares of the company’s stock valued at $581,610,000 after buying an additional 1,124,747 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Kymera Therapeutics by 20.8% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 6,159,335 shares of the company’s stock valued at $479,258,000 after buying an additional 1,061,957 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of Kymera Therapeutics by 15.6% during the 4th quarter. Vanguard Group Inc. now owns 6,267,644 shares of the company’s stock valued at $487,685,000 after acquiring an additional 845,922 shares during the period.

Kymera Therapeutics Price Performance

KYMR stock opened at $121.50 on Friday. Kymera Therapeutics, Inc. has a 1-year low of $39.84 and a 1-year high of $130.05. The business has a 50 day simple moving average of $108.75 and a two-hundred day simple moving average of $91.84. The company has a market capitalization of $10.10 billion, a price-to-earnings ratio of -37.50 and a beta of 1.95.

Kymera Therapeutics (NASDAQ:KYMR) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($0.62) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The firm had revenue of $65.00 million for the quarter, compared to analysts’ expectations of $32.78 million. During the same quarter last year, the business posted ($0.95) earnings per share. The company’s revenue for the quarter was up 465.2% compared to the same quarter last year. Sell-side analysts anticipate that Kymera Therapeutics, Inc. will post -3.75 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on KYMR shares. Barclays raised their target price on shares of Kymera Therapeutics from $133.00 to $139.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Brookline Capital Markets reissued a “buy” rating on shares of Kymera Therapeutics in a research note on Monday, June 8th. Oppenheimer restated an “outperform” rating and set a $125.00 price objective on shares of Kymera Therapeutics in a research report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Friday, July 17th. Finally, Guggenheim upped their target price on shares of Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Tuesday, July 28th. Twenty analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $125.65.

Insider Buying and Selling

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction on Monday, June 29th. The shares were sold at an average price of $109.48, for a total value of $3,424,862.84. Following the sale, the director owned 461,794 shares in the company, valued at $50,557,207.12. The trade was a 6.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the transaction, the director directly owned 240,123 shares of the company’s stock, valued at $25,573,099.50. This trade represents a 86.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 3,604,813 shares of company stock worth $387,557,004 in the last 90 days. 15.98% of the stock is owned by company insiders.

Kymera Therapeutics Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.